These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 24091833)

  • 1. Harnessing PD-L1-specific cytotoxic T cells for anti-leukemia immunotherapy to defeat mechanisms of immune escape mediated by the PD-1 pathway.
    Ahmad SM; Larsen SK; Svane IM; Andersen MH
    Leukemia; 2014 Jan; 28(1):236-8. PubMed ID: 24091833
    [No Abstract]   [Full Text] [Related]  

  • 2. The stimulation of PD-L1-specific cytotoxic T lymphocytes can both directly and indirectly enhance antileukemic immunity.
    Ahmad SM; Svane IM; Andersen MH
    Blood Cancer J; 2014 Jul; 4(7):e230. PubMed ID: 25036801
    [No Abstract]   [Full Text] [Related]  

  • 3. In acute myeloid leukemia, B7-H1 (PD-L1) protection of blasts from cytotoxic T cells is induced by TLR ligands and interferon-gamma and can be reversed using MEK inhibitors.
    Berthon C; Driss V; Liu J; Kuranda K; Leleu X; Jouy N; Hetuin D; Quesnel B
    Cancer Immunol Immunother; 2010 Dec; 59(12):1839-49. PubMed ID: 20814675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of TLR4 and B7-H1 on immune escape of urothelial bladder cancer and its clinical significance.
    Wang YH; Cao YW; Yang XC; Niu HT; Sun LJ; Wang XS; Liu J
    Asian Pac J Cancer Prev; 2014; 15(3):1321-6. PubMed ID: 24606459
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor Escape Phenotype in Bladder Cancer Is Associated with Loss of HLA Class I Expression, T-Cell Exclusion and Stromal Changes.
    Gil-Julio H; Perea F; Rodriguez-Nicolas A; Cozar JM; González-Ramirez AR; Concha A; Garrido F; Aptsiauri N; Ruiz-Cabello F
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34298868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Programmed Death-Ligand 1 on Antigen-presenting Cells Facilitates the Induction of Antigen-specific Cytotoxic T Lymphocytes: Application to Adoptive T-Cell Immunotherapy.
    Goto T; Nishida T; Takagi E; Miyao K; Koyama D; Sakemura R; Hanajiri R; Watanabe K; Imahashi N; Terakura S; Murata M; Kiyoi H
    J Immunother; 2016 Oct; 39(8):306-15. PubMed ID: 27548033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD-1 /PD-L1 checkpoint in hematological malignancies.
    Annibali O; Crescenzi A; Tomarchio V; Pagano A; Bianchi A; Grifoni A; Avvisati G
    Leuk Res; 2018 Apr; 67():45-55. PubMed ID: 29428449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells.
    Barsoum IB; Smallwood CA; Siemens DR; Graham CH
    Cancer Res; 2014 Feb; 74(3):665-74. PubMed ID: 24336068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exosomal PD-L1: Roles in Tumor Progression and Immunotherapy.
    Morrissey SM; Yan J
    Trends Cancer; 2020 Jul; 6(7):550-558. PubMed ID: 32610067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A TLR3-Specific Adjuvant Relieves Innate Resistance to PD-L1 Blockade without Cytokine Toxicity in Tumor Vaccine Immunotherapy.
    Takeda Y; Kataoka K; Yamagishi J; Ogawa S; Seya T; Matsumoto M
    Cell Rep; 2017 May; 19(9):1874-1887. PubMed ID: 28564605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity.
    Yonesaka K; Haratani K; Takamura S; Sakai H; Kato R; Takegawa N; Takahama T; Tanaka K; Hayashi H; Takeda M; Kato S; Maenishi O; Sakai K; Chiba Y; Okabe T; Kudo K; Hasegawa Y; Kaneda H; Yamato M; Hirotani K; Miyazawa M; Nishio K; Nakagawa K
    Clin Cancer Res; 2018 Jun; 24(11):2653-2664. PubMed ID: 29530936
    [No Abstract]   [Full Text] [Related]  

  • 12. The perivascular microenvironment in Epstein-Barr virus positive primary central nervous system lymphoma: The role of programmed cell death 1 and programmed cell death ligand 1.
    Sugita Y; Furuta T; Ohshima K; Komaki S; Miyoshi J; Morioka M; Abe H; Nozawa T; Fujii Y; Takahashi H; Kakita A
    Neuropathology; 2018 Apr; 38(2):125-134. PubMed ID: 29067721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape.
    Jiang X; Wang J; Deng X; Xiong F; Ge J; Xiang B; Wu X; Ma J; Zhou M; Li X; Li Y; Li G; Xiong W; Guo C; Zeng Z
    Mol Cancer; 2019 Jan; 18(1):10. PubMed ID: 30646912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. T-cell epitope strength in WAP-T mouse mammary carcinomas is an important determinant in PD1/PD-L1 immune checkpoint blockade therapy.
    Bruns M; Wanger J; Schumacher U; Deppert W
    Oncotarget; 2016 Oct; 7(40):64543-64559. PubMed ID: 27579535
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway.
    Liu J; Hamrouni A; Wolowiec D; Coiteux V; Kuliczkowski K; Hetuin D; Saudemont A; Quesnel B
    Blood; 2007 Jul; 110(1):296-304. PubMed ID: 17363736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In a model of tumor dormancy, long-term persistent leukemic cells have increased B7-H1 and B7.1 expression and resist CTL-mediated lysis.
    Saudemont A; Quesnel B
    Blood; 2004 Oct; 104(7):2124-33. PubMed ID: 15191948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MiR-195/-16 Family Enhances Radiotherapy via T Cell Activation in the Tumor Microenvironment by Blocking the PD-L1 Immune Checkpoint.
    Tao Z; Xu S; Ruan H; Wang T; Song W; Qian L; Chen K
    Cell Physiol Biochem; 2018; 48(2):801-814. PubMed ID: 30032144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-L1 Expression and Tumor-infiltrating Lymphocytes in Uterine Smooth Muscle Tumors: Implications for Immunotherapy.
    Shanes ED; Friedman LA; Mills AM
    Am J Surg Pathol; 2019 Jun; 43(6):792-801. PubMed ID: 31009388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure).
    Kim JM; Chen DS
    Ann Oncol; 2016 Aug; 27(8):1492-504. PubMed ID: 27207108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T Cells Deficient in Diacylglycerol Kinase ζ Are Resistant to PD-1 Inhibition and Help Create Persistent Host Immunity to Leukemia.
    Jing W; Gershan JA; Holzhauer S; Weber J; Palen K; McOlash L; Pulakanti K; Wesley E; Rao S; Johnson BD; Riese MJ
    Cancer Res; 2017 Oct; 77(20):5676-5686. PubMed ID: 28916658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.